We are a biopharmaceutical company focused on the discovery, development and
commercialization of innovative antibiotics for serious infections. We are
developing tedizolid phosphate, a new, novel antibiotic, for the treatment of
serious Gram-positive bacterial infections, including those caused by
methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is
being developed for acute bacterial skin and skin structure infections, or
ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the
current classification for complicated skin and skin structure infections. In
addition, we are discovering antibiotics for infections caused by Gram-negative
bacteria using our structure based discovery platform.
In December 2011, we reported top line data from our first Phase 3 clinical
trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid
phosphate for the treatment of ABSSSI.